as 12-11-2024 4:00pm EST
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 12.3M | IPO Year: | 2021 |
Target Price: | $4.33 | AVG Volume (30 days): | 443.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.19 | EPS Growth: | N/A |
52 Week Low/High: | $0.38 - $1.94 | Next Earning Date: | 11-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SNSE Breaking Stock News: Dive into SNSE Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
4 months ago
GlobeNewswire
6 months ago
The information presented on this page, "SNSE Sensei Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.